恒瑞医药(01276.HK)拟4001.44 万元收购控股子公司成都盛迪1.4587%股权

智通财经
25 Jul
【恒瑞医药(01276.HK)拟4001.44 万元收购控股子公司成都盛迪1.4587%股权】智通财经APP讯,恒瑞医药(01276.HK)公布,为优化控股子公司股权结构,公司拟以现金 4001.44 万元收购刘疆、周云曙、蒋素梅、孙绪根、卢正清、蒋新华、袁开红、陈永江、吴玉霞合计持有的成都盛迪医药有限公司1.4587%股权,其他股东放弃优先购买权。本次交易完成后,公司将持有成都盛迪 97.3866%股权,合并报表范围不会因本次股权收购而发生变化。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10